An observational study in COVID-19, Lung Cancer and Lung TB, sponsored by Lung Center of the Philippines. Completed at 1 site in Philippines. Per ClinicalTrials.gov, last updated 2022-11-09.
Sponsored by Lung Center of the Philippines · Observational
This study will determine the outcomes of anatomic lung resections in patients who recovered from coronavirus disease 2019 (COVID-19) disease by describing the morbidity and mortality as well as the length of postoperative hospital stay.
This study will be conducted at the Lung Center of the Philippines. The study design is a retrospective case series implemented via chart review. Online and written patient records will be reviewed to determine the baseline patient characteristics and the preoperative outcomes. Patients who recovered from COVID-19 will be selected from those who underwent anatomic lung resection from June 1, 2020 to May 31, 2022. This study will be done in accordance with the Helsinky Declaration and Good Clinical Practice Guidelines, and will be subject for approval of the institutional Ethics and Technical Review Boards. Descriptive statistics will be used to describe patient characteristics and perioperative outcomes.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's enrollment of 16 is below the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →This is the only study on the registry with Lung Center of the Philippines as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients who recovered from COVID-19, and who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
patients with previous COVID-19 infection who underwent anatomic lung resection (segmentectomy, lobectomy, bilobectomy or pneumonectomy)
Procedure: anatomic lung resection
includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
Mortality rate
proportion of patients who died due to perioperative complications
Time frame: perioperative period (up to 30 days after anatomic lung resection)
Major complication rate
proportion of patients who develop acute kidney injury, acute myocardial infarction, acute respiratory distress syndrome (ARDS), acute respiratory failure, atelectasis requiring intervention, bronchopleural fistula, empyema thoracis, hemothorax, pneumonia, stroke or venous thromboembolism
Time frame: perioperative period (up to 30 days after anatomic lung resection)
Minor complication rate
proportion of patients who develop atrial fibrillation, pneumothorax or prolonged air leak
Time frame: perioperative period (within 30 days after anatomic lung resection)
Length of postoperative hospital stay
time duration from surgery to discharge order
Time frame: perioperative period (up to 30 days after anatomic lung resection)
Plan to share: Yes — Patient baseline characteristics and outcomes
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: 5 years
Ran from Oct 2022 to primary completion in Oct 2022, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.